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Angiotensin I converting enzyme gene polymorphism in non-insulin
dependent diabetes mellitus. A total of 168 patients with non-insulin
dependent diabetes (NIDDM) followed over 10 years were recruited in
this study. The patients were divided into two groups: Group I patients
had a stable renal function (N = 96) and Group 2 had a declining renal
function (N = 72). Group 1 included those whose serum creatinine was
normal five years ago but had increased to  2 mg/dt or those who has
reached end-stage renal failure (requiring dialysis) by the time of study.
All patients were genotypcd for the insertion/deletion (lID) polymorphism
of the ACE gene, the M235T polymorphism of the angiotensinogen (Atg)
gene and the A1166C polymorphism of the angiotensin II type 1 receptor
(AT1) gene. The genotype frequency distributions of M235T Atg and the
A116C AT1 gene polymorphisms were not different between Group 1
versus Group 2. While the frequency of the ACE DD genotype in Group
1 (7.3%) was comparable to that of the general population, the DD
frequency was significantly higher in Group 2 (26.4%) than in Group 1
(odds ratio, 4.56; 95% confidence interval, 1.80 — 11.56, P < 0.001).
Among all 168 patients studied, the renal survival rate was significantly
lower among DD than ID (P < 0.005) or II patients (P < 0.001). In
patients with a declining renal function (Group 2), those with the DD
genotype had a significantly shorter time interval from onset of diabetes to
the initiation of dialysis (13.4 1.4 years) than those with ID (20.7 1.2
years, P < 0.01) or II genotypes (17.5 1.1 year, P < 0.01). Analysis of the
clinical course of the three ACE genotypes revealed that the majority
(95%) of patients with the DD genotype who had albuminuria progressed
to end-stage renal disease within 10 years of diagnosis of diabetes. Our
analysis also revealed that initiation and continuation of dialysis are
associated with a progressive decrease in the frequency of the DD
genotype. These results indicate that, in NIDDM, the ACE DD genotype
has a high prognostic value for progressive deterioration of renal function.
Moreover, the DD genotype appears to increase the mortality once
dialysis is initiated.
As in other industrial countries, diabetic nephropathy is an
important cause of end-stage renal disease in Japan, accounting
for approximately 30% of patients on dialysis. A recent multi-
center study in the United States established that ACE inhibition
attenuates progressive decline of renal function in patients with
insulin dependent diabetes mellitus (IDDM) [11. This confirms
Received for publication October 30, 1995
and in revised form March 8, 1996
Accepted for publication March 11, 1996
© 1996 by the International Society of Nephrology
the notion established in animal studies that the renin-angiotensin
system (RAS) plays an important pathogenic role in the process of
progressive loss of renal function, common to a variety of chronic
renal diseases [21.
It is now recognized that the activity of RAS is regulated not
only by renin and by angiotensin receptors, but also by other
components of the system, specifically, availability of angio-
tensinogen (Atg) and the activity of the angiotensin converting
enzyme (ACE) [3]. In this regard, human genetic studies have
revealed that the genes of RAS are highly polymorphic, raising
the possibility that, in addition to environmental factors, the
genetic make-up of RAS affects the status of RAS in individuals.
One such polymorphism is the insertion/deletion polymorphism
of the ACE gene. The ACE gene consists of 26 exons and spans
21 kb on chromosome 17. Within intron 16, a polymorphism
exists, consisting of the presence or absence of a 287 base pair
fragment. While this deletion polymorphism is associated with
elevated serum and cellular ACE levels [4—6], its association with
blood pressure levels or ischemic heart disease varies among
populations of different genetic and environmental backgrounds
[7—12].
Other studies indicate that gene variants of other components
of RAS also affect the risk of hypertension and cardiac disease, A
point mutation of nucleic acid at codon 235 in the Atg gene leads
to an amino acid substitution of threonine for methionine. This
Atg M235T polymorphism has been associated with variations in
plasma concentration of Atg [13], hypertension [13, 141 and
coronary heart disease, and independently as well as synergisti-
cally with ACE insertion/deletion (I/D) polymorphism [15, 16].
Finally, a nucleic acid substitution of A with C at position 1166 in
the angiotensin type 1 receptor (AT1) gene (A1166C) has been
identified and associated with hypertension [171. The A1166C
polymorphism has also been shown, synergistically with the ACE
I/D polymorphism, to predict the risk of coronary heart disease
[18]. Given the most recent findings by us [19, 20] and others [21]
indicating that the deletion polymorphism in the ACE gene is
significantly associated with the progressive loss of renal function
in patients with IgA nephropathy, it appeared possible that ATI
and Atg gene polymorphisms may, synergistically with the ACE
gene, affect the prognosis of renal diseases, as well.
Studies of patients with insulin-dependent diabetes mellitus
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(IDDM) indicate that genetic factors contribute to susceptibility
to nephropathy [22, 23]. Although results are variable [24], some
studies [25, 261 show that, in patients with early IDDM, ACE l/D
polymorphism is associated with development of microalbumin-
uria or proteinuria, which are considered prodrome to progressive
renal failure. In non-insulin dependent diabetes mellitus
(NIDDM), some 15 to 20% of patients develop renal failure. As
more than 90% of patients with diabetes mellitus are classified as
NIDDM, the majority of chronic renal failure in diabetic patients
occurs in NIDDM individuals. A study suggested that some, as yet
undefined, genetic factor(s) predispose NIDDM to progressive
renal failure [23]. Relevant to our current investigation are recent
observations that ACE inhibition preserves renal function in
NIDDM [271. Moreover, a preliminary study further suggests that
ACE inhibitor is similarly effective in hypertensive NIDDM
patients [281. It is therefore conceivable that the reniri-angiotensin
system is involved in the progression of diabetic nephropathy.
Of interest, a recent study by Schmidt, Schone and Ritz [24]
showed that no significant difference exists in the frequency of
ACE genotypes between NIDDM patients with diabetic nephrop-
athy versus without it, as defined by microalbuminuria. Thus, the
ACE gene polymorphism appears to have little impact on the onset
of nephropathy or albuminuria in NIDDM. Given the above-
described abundant evidence for the involvement of the renin-
angiotensin system in the progression of diabetic nephropathy, it
appeared warranted to ascertain the role of genotype within the
renin-angiotensin system in determining the prognosis of renal
function in NIDDM patients.
Methods
Table 1. Clinical and laboratory features of Groups 1 and 2
Group 1
(N=96)
Group 2
(N=72) P
Age years 63.8 1.0 61.1 1.1 NS
Sex (male:female)a 63:31 49:23 NS
Blood pressure mm Hg
Systolic 139.9 2.1 145.6 3.1 NS
Diastolic 78.5 1.2 79.1 1.4 NS
HbAIC %" 9.2 0.1 8.1 0.2 <0.0001
Cholesterol mg/dl 202.1 4.2 200.9 8.1 NS
Duration in years from 20.4 0.6 18.7 0.8 NS
onset of diabetes to study
% Of patients with retinopathy 48% (46) 100% (72) <0.0001
% Of patients with albuminuriaa 38% (36) 100% (72) <0.0001
Microalbuminuria 18% (17) 0% (0) <0.0001
Overt proteinuria 20% (19) 100% (72) <0.0001
% Of patient on dialysi?
Serum creatinine"
0% (0)
0.77 0.02
94% (68)
>8.7 0.4
<0.000 1
<0.0001
Range 0.4—1.8 2.1—>12.8
Values are given as means
albuminuria, 19 had overt proteinuria, demonstrated by standard dipstick
techniques on at least 3 consecutive occasions. The mean duration of
diabetes in subgroups of Group 1 with microalbuminuria and with overt
proteinuria were 22.5 1.5 years (13—34 years) and 23.5 1.7 years
(18—39 years), respectively. The mean age was indistinguishable between
patients with microalbuminuria (66.1 2.5 years) in Group 1 versus
Group 2, and between patients with albuminuria (64.1 3.1 years) in
Group 1 versus Group 2. The clinical and laboratory features were
comparable between Group 2 versus these 2 subgroups of Group 1
patients with albuminuria.
Data were compared between Group 1 and Group 2 by multiple
contingency table analysish Data were compared between Group 1 and Group 2 by one way
ANOVA with factorial analysis
SE. Of the 36 Group 1 patients with
Patient population
Approximately 6000 patients with NIDDM were seen in the
diabetic clinic of Saiseikai Central Hospital, Tokyo, from Septem-
ber 1994 to March 1994. Those who satisfied the following criteria
were recruited sequentially in our study: (1) having been followed
for > 10 years since onset of diabetes; (2) having had regular
measurement of serum creatinine and hemoglobin Ale for  five
years; (3) having provided informed consent. Diabetes was de-
fined as fasting plasma glucose  140 mgldl or a two hours
post-load plasma glucose level  200 mg/dl.
A total of 168 patients fulfilled the above criteria. They were
divided into two groups, that is, 96 patients with stable renal
function (Group 1) and 72 patients with declining renal function
(Group 2).1 The criteria for 'declining renal function' follows that
of Lewis et al [1], and includes patients whose serum creatinine
was normal five years ago but had doubled (or more than
doubled) to reach levels 2 mgldl prior to study (N = 9) and
those who had reached end-stage renal failure, requiring dialysis
'The actual number of patients who fulfilled the above defined three
criteria was 173, and, of those, 77 had declining renal function. Of note, a
biopsy study by Parving et a! [31] in NIDDM patients with albuminuria
demonstrated that albuminuria secondary to non-diabetic renal lesions
does not accompany diabetic retinopathy. This indicates that diabetic
retinopathy is an important marker for diabetic nephropathy in patients
with albuminuria. Of the 77 patients initially identified, we excluded five
patients who lacked retinopathy. As a result, the total number of patients
as well as the number of patients in Group 2 decreased to 168 and 72,
respectively. Statistical analysis was performed for Group 2 with or
without the 5 excluded patients (see Footnote 2).
before the study (N = 63). The remaining patients are defined to
have 'stable renal function.'
The clinical and laboratory features of Group 1 and Group 2
patients are summarized in Table 1. These two groups were
comparable in age. The systolic and diastolic blood pressures were
not significantly different between Group 1 (139.9 2.1/78.5
1.2 mm Hg) and Group 2 (145.6 3.1/79.1 1.4 mm Hg). The
mean value of Hb Aic was slightly lower in Group 2 (8.1 0.2%)
than Group 1 (9.2 0.1%, P < 0.05). Cholesterol levels were not
different in the two groups.
Al! 72 patients in Group 2 (declining renal function) had overt
proteinuria. Seventeen patients (18%) in Group 1 had microalbu-
minuria (urinary albumin excretion rate  20 j.tg/min on at least
2 consecutive occasions), and 19 patients (20%) in Group 1 had
overt proteinuria. Other conditions such as congestive heart
failure, urinary tract infection, benign nephrosclerosis or super-
imposed primary glomerulonephritis, may cause albuminuria in
NIDDM [29, 30]. Also, the absence of detectable retinal lesions
was taken to be incompatible with the diagnosis of diabetic
nephropathy, even in long-standing diabetes [31]. We, therefore,
also evaluated all the patients for retinopathy. All 72 patients in
Group 2 had retinopathy and were thus considered to have
diabetic nephropathy.1 Forty-six patients (48%) of Group 1 had
retinopathy.
Detennination of genotypes
In accord with the method already described elsewhere [19],
genomic DNA was extracted from peripheral blood with a blood
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DNA kit (QIAGEN, Chatsworth, CA, USA). Genomic DNA was
suspended in 10 msi Tris-HC1, 1 m EDTA, pH. 8.0, and
concentrations were measured by spectrophotometry.
To determine the ACE genotype of the patients, a genomic
DNA fragment on intron 16 of the ACE gene was amplified by
polymerase chain reaction (PCR) using a flanking primer pair [321
and a primer pair that recognizes insertion-specific sequence [33].
The flanking primer pair used were 5'-CTGGAGACCACTC-
CCATCCTITFCT and 5 '-GATGTGGCCATCACATFCGTCA-
GAT. PCR amplification products were obtained using 50 l
reactions [1 ig genomic DNA, 500 pmol of primers, 0.5 m each
of deoxy-ATP, GTP, CTP, TTP, and 3 mrvi MgC12; 1 unit of Taq
DNA polymerase (Takara, Ootsu, Shiga, Japan); 50 mivi KC1;
0.001% gelatin; and 10 msi Tris-HC1, pH 8.3] with 10 miiiutes of
denaturation at 94°C, followed by 30 cycles of one minute at 94°C,
one minute at 58°C (annealing), and two minutes at 72°C (exten-
sion) in a thermal cycler (PC-700, ASTEC, Fukuoka, Japan).
Reaction was terminated at 72°C for two minutes. Fragments
without insertion (D allele) and with insertion (I allele) of -—190
and —490 bp, respectively, were detected on a 1.5% agarose-gel
containing ethidium bromide. To increase the specificity of DD
genotyping, PCR amplifications were performed with an inser-
tion-specific primer pair (5'TGGGACCACAGCGCCCGCCAC-
TAC3' and 5'TCGCCAGCCCTCCCATGCCCATAA3') [33],
with 25 l reactions [0.5 j.g genomic DNA; 500 pmol of primers;
0.5 m each of deoxy-ATP, GTP, CTP, TTP, and 1.5 mM MgC12;
0.5 unit of Taq DNA polymerase (Takara, Ootsu, Shiga, Japan);
50 mM KC1; 0.001% gelatin; and 10 mM Tris-HC1, pH 8.3] with
one minute of denaturation at 94°C, followed by 30 cycles of 30
seconds at 94°C, 45 seconds at 67°C (annealing), and two minutes
at 72°C (extension). Only the I allele produces a 335-bp amplicon.
The 335-bp fragment was identified on a 1.5% agarose-gel
containing ethidium bromide. The reaction yields no products in
the samples of DD genotype.
To determine the Atg M235T genotype, a genomic DNA
fragment of the Atg gene was amplified by PCR [341. The primer
pair used were 5'-GATGCGCACAAGGTCCTGTC and 5'-
CAGGGTGTCCACACTGGGTCGC. PCR amplification prod-
ucts were obtained using 30 jil reactions [1 .tg genomic DNA, 500
pmol of primers, 125 mM each of deoxy-ATP, GTP, CTP, TIP,
and 1.5 msi MgCl2; 1 unit of Taq DNA polymerase; 50 msi KC1;
0.001% gelatin; and 10 mivi Tris-HC1, pH 8.3] with five minutes of
denaturation at 94°C, followed by 30 cycles of one minute at 94°C,
one minute at 61°C (annealing), and one minute at 72°C (exten-
sion) in a thermal cycler. Reaction was terminated at 72°C for two
minutes. Because the most 3' guanosine residue in the latter
primer is mismatched with the Atg gene of genomic DNA, during
the amplification SfaNI restriction site is created in the presence
of the Atg M235 allele, but not the 235T allele. After an overnight
restriction endonuclease digestion at 37°C with SfaN-I (New
England Biolabs, Beverly, MA, USA), the amplified Atg gene
fragments were separated by polyacrylamide-gel electrophoresis.
Fragments without M235 allele and with 235T allele of —-266 and
-—303 bp, respectively, were detected on a in 10% polyacrylamide
TBE Ready Gel (Bio Rad, Hercules, CA, USA) stained with
ethidium bromide.
To determine the AT1 A1166C genotype, we performed allele-
specific oligonucleotide hybridization. A genomic DNA fragment
of the AT1 gene was amplified by PCR [17, 18]. The primer pair
used were 5' - AAATGCTTGTAGCCAAAGTCACCT and 5' -
'TTCATACTCATTCAAGGTAGTCT. PCR amplification prod-
ucts were obtained using 25 1d reactions [1 ig genomic DNA, 500
pmol of primers, 125 m each of deoxy-ATP, GTP, CTP, TFP,
and 1.5 msi MgCl2; 1 unit of Taq DNA polymerase; 50 mrvi KC1;
0.001% gelatin; and 10 mrvi Tris-HC1, pH 8.3] with five minutes
denaturation at 94°C, followed by 30 cycles of one minute at 94°C,
one minute at 60°C (annealing), and one minute at 72°C (exten-
sion) in a thermal cycler. The reaction was terminated at 72°C for
two minutes. Amplified PCR products were denatured in 0.4
mol/liter NaOH and 10 mmol/liter EDTA, blotted in duplicate
onto nylon membrane (Hyband N, Amasham), neutralized in 1
mol/liter ammonium acetate (pH 7.0), and baked at 80°C for two
hours. Each membrane was then hybridized for 12 hours in Easy
Hybe (Boehringer Mannheim, GmbH, Germany) solution with
digoxygenin (DIG) UI? end-labeled 15-mer oligonucleotide
probes. These probes were A1166-AATGAGG4YFAGCTA and
C1166-AATGAGCCTTAGCTA. Hybridizations were done at
23°C for 33 pmol of A1166 oligoprobe and at 33°C for 66 pmol of
C1166 oligoprobe. The membranes were washed twice with x2
SDS and 0.1% sodium dodecyl sulfate (SDS) for 10 minutes and
with 0.1 X SDS and 0.1% SDS for 30 minutes at the same
temperature as the hybridization. Hybridized oligoprobes were
visualized by immunological reaction with using DIG-detection
Kit (Boehringer Mannheim, GmbH, Germany). Depending on
the nucleotide sequence at bp 1166 of AT1 gene, A1166 oligo-
probe hybridizes to AT1 A1166 allele at 23°C but not Cl 166
allele, and A1166 oligoprobe hybridizes to AT1 C1166 allele at
33°C but not A1166 allele. To confirm the A1166C genotype, PCR
amplicons of AT1 gene were digested with Dde-i (Toyobo,
Osaka, Japan) at 37°C overnight. Since A to C transition at
position 1166 in AT1 gene generate an additional recognition site
for restriction site for Dde-i, the ii66C allele and the ii66A
allele were separated on a 10% polyacrylamide TBE Ready Gel.
Statistical analyses
The genotypes and allele frequencies for the ACE l/D poly-
morphism were tested by the multiple contingency table analysis
for their association with decreased renal function. Odds ratios
were calculated as a measure of the association of the ACE
genotype with the loss of renal function. For each odds ratio, we
calculated a 95% confidence interval and two-tailed P values. The
patients with declining renal function (Group 2) were compared
with the patients with stable renal function (Group 1). For the
analysis of the time course from the onset of diabetes to the
initiation of chronic dialysis, a survival analysis using Kaplan-
Meier method with the log-rank test statistic was performed.
These data were not adjusted for age. P < 0.05 was regarded as
being statistically significant.
Results
In NIDDM patients with stable renal function (Group 1), the
frequencies of the DD, ID, and II genotypes of ACE gene were
7.3%, 47.9%, and 44.8%, respectively (Table 2). These data are
similar to the published data for the general Japanese population
[19, 35, 36]. The values predicted by the assumption of Hardy-
Weinberg equilibrium in Group 1 (DD:ID:II = 9.8%:43.0%:
47.2%, NS) were similar to those observed in these patients. In
patients with declining renal function (Group 2), however, the
frequencies of genotype (DD:ID:II = 26.4%:38.9%:34.7%) were
significantly different from those seen in Group 1 (Table 2; x =
660 Yoshida et al: ACE gene polymorphism in diabetic nephropathy
Table 2. Genotype frequencies in patients with stable renal function
(Group 1) and declining renal function (Group 2)
N
ACE genoty
(deletion/insert
DD ID
pe
ion)
II
At
TT
g genotype
(M235T)
MT MM
AT
(
CC
I genotype
Al 166C)
AC AA
Group 1 96 7 46 43 61 32 3 2 16 78
Group 2 72 19 28
11.49
25 44 26 2
0.15
0 12 60
1.52
P <0.01 NS NS
Data were compared between Group 1 and Group 2 by multiple
contingency table analysis.
Abbreviations are: ACE; angiotensin I converting enzyme, Atg; angio-
tensinogen, AT1; angiotensin II type 1 receptor, NS; not significant.
11.49, P < 0.01).2 The observed genotype distribution in Group 2
was not significantly different from that predicted by the Hardy-
Weinberg equilibrium (DD:ID:1I = 21.0%:49.7%:29.3%, NS).
In the Atg gene, the frequency distribution for M235T poly-
morphism was not significantly different between Group I and 2
(x2 = 0.15, NS; Table 2). This pattern of genotype distribution is
similar to published data for the general Japanese population [161.
In the ATI gene, the frequency distribution for the A1166C
polymorphism in Group 2 patients was also similar to that in
Group 1 patients (x2 = 1.52, NS; Table 2). Again, these frequen-
cies are similar to data for healthy Japanese population (AA:AC:
CC = 83%:17%:0%). Genotype distributions of the two polymor-
phisms in both groups were in Hardy-Weinberg equilibrium.
To test the effect of the ACE II genotype as a marker for
reduced risk of progressive diabetic nephropathy, the ratio of II
versus the combined frequency of ID and DD in Group 2 was
compared with this ratio in Group 1. The II genotype was not
significantly less frequent in Group 2 (DD+ID:II = 65.3%:
34.7%) than Group 1 (DD+ID:II = 55.2%:44.8%, odds ratio,
1.52; 95% confidence interval, 0.81 to 2.86, NS).
To estimate the relative risk of progressive loss of renal
function imparted by the DD genotype, the ratio of the DD
genotype versus the pooled frequency of the ID and II genotypes
in Group 2 was compared with this ratio in Group 1. The DD
genotype was significantly more frequent in Group 2 patients with
declining renal function (DD:ID+II = 26.3%:73.7%) than in
Group 1 patients with stable renal function (DD:ID+II = 7.3%:
92.8%, odds ratio, 4.56; 95% confidence interval, 1.80 - 11.56,
P < 0.001).
As shown in Table 1, Group I patients with stable renal
function included 36 patients with albuminuria, and 60 patients
without albuminuria. The frequency of the DD genotype in Group
1 patients with albuminuria (DD:ID+II = 2.7%:97.3%) was not
significantly different from those without albuminuria (DD:
ID+II = 10.3%:89.7%, NS; Table 3). However, the DD genotype
was more frequent in Group 2 patients than in Group 1 patients
with albuminuria (y = 9.15 P < 0.005) or without albuminuria( = 5.32, P < 0.05; Table 3).
2 In our study, 5 patients with declining renal function, but without
retinopathy, were excluded from Group 2. Of these 5 patients, 3 patients
had DD genotype, one had ID, and one had II genotype. When we include
these 5 patients in Group 2, statistical analysis reveals a significant
difference in the frequency of ACE genotype between Group 1 and Group
2 (g = 13.87, P < 0.0005).
Table 3. Frequencies of ACE DD vs. other genotypes in Group 1
patients with or without albuminuria, and Group 2 patients
vs. Patients with
ACE genotypes vs. Group 2 albuminuria
N DD ID+II x2
Group 1 without 60 6 54 5.32a 1.93
albuminuria
Group 1 with 36 1 35 915h —
albuminuria
Group2 72 19 53 — —
Data were compared between Group 1 patients with or without
albiminuria versus Group 2, or between Group I patients with versus
without albuminuria by multiple contingency table analysis. All Group 2
patients had albuminuria.
ap <0.05
b P < 0.005
Table 4. Frequencies for combined genotypes for ACE I/D, Atg
M235T and AT1 A1166C polymorphisms in Group 1 vs. Group 2
ACE genotype
OddsGroup 1 Group 2
DD ID + 11 DD ID + II ratio 95% CI ,2
Atg(M235T)
TT 4 57 10 34 4.19a 1.21—i4.40 5.784
MT + MM 3 32 9 19 5.05a 1.21—21.00 5.605
AT1(A1166C)
CC + AC 2 16 6 6 8.00 1.25—51.14 4.568
AA 5 73 13 47 4.04 l.35—12.07 6.959
Data were compared between Group 1 with stable renal function and
Group 2 with declining renal function. Odds ratios were unadjusted for
age. Abbreviations are: CI; confidence interval, ACE; angiotensin I
converting enzyme, I/D; insertion/deletion, Atg, angiotensinogen; AT1;
angiotensin II type 1 receptor.
ap <0.05
We also evaluated ACE l/D genotype distribution in terms of
retinopathy. Within Group 1, 46 patients had retinopathy. The
frequency of DD genotype in these patients (DD:ID+II =
6.5%:93.5%) was not significantly different from Group I patients
without retinopathy (DD:ID+II = 8.0%:92.0%, = 0.92, NS).
However, the DD genotype in patients with declining renal
function (Group 2) was significantly more frequent than in Group
1 patients with retinopathy ( = 7.30, P < 0.05) or without
retinopathy ( = 6.29, P < 0.05).
To further identify a genetic risk for progressive loss of renal
function, we tested a synergistic effect of the ACE DD genotype
and the Yr genotype of Atg polymorphism (Table 4). The
frequency of ACE DD genotype in Group 2 patients with
declining renal function was higher than that in Group 1 patients
with stable renal function, regardless of the Atg genotype (odds
ratio, 4.19; 95% confidence interval, 1.21 — 14.40,P < 0.05 for TT
vs. odds ratio, 5.05; 95% confidence interval, 1.21 - 21.00, P <
0.05 for non-lIT). The combined effects of ACE DD genotype and
AA genotype of AT1 polymorphism was then analyzed (Table 4).
In patients with and without ATI AA genotype, the ACE DD
genotype in Group 2 was more frequent than that in Group 1
(odds ratio, 4.04; 95% confidence interval, 1.35 — 12.07, P < 0.05
for AA vs. odds ratio, 8.00; 95% confidence interval, 1.25 — 51.14,
P < 0.05 for non-AA).
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DD
(N = 26)
ID
(N = 74)
II
(N = 68) P
Age years 59.7 1.9 62.5 1.3 61.2 1 NS
Blood pressure mm Hg
Systolic 139.1 3.0 144.9 3.0 140.0 2.8 NS
Diastolic 76.4 2.4 79.7 1.6 78.9 1.4 NS
Hb A1C % 9.2 0.4 9.5 0.2 9.0 0.2 NS
Cholesterol mg/dl 218.5 17.4 205.5 6.4 195.1 5.8 NS
Sex(male:female)a 17:9 47:27 49:19 NS
Duration of diabetes
years 17.4 1.2 20.2 0.7 20.0 0.8 NS
% Patients with 85% (22) 69% (51) 66% (45) NS
retinopathya
% Patients with 77% (20) 61% (45) 63% (43) NS
albuminuria'
% Patients on dialysis' 65% (17) 37% (27) 28% (19) <0.005
Serum creatinine mgldl 5.6 1 3.5 0.5 2.8 0.5 <0.05
To examine the effect of the ACE polymorphism on the clinical
course, we next compared the time lag from the identifiable onset
of diabetes to initiation of dialysis among DD, ID and II geno-
types. The characteristics of the three genotypes were comparable
in terms of age, sex, duration of diabetes, blood pressure, HbA1C
levels, and prevalence of retinopathy (Table 5). Although the
frequency of albuminuria in the DD genotype was not significantly
higher than in ID and II genotype, both the prevalence of dialyis
and the level of serum creatinine were significantly higher (P <
0.05). Figure 1 shows the survival curves for the kidney as a
functioning organ in all patients. The "renal survival rate" in
patients with DD genotype (15 years, 56.1%; 20 years, 43.8%; 25
years, 28.8%) was lower than that in patients with ID (15 years,
92.8%; 20 years, 65.7%; 25 years, 54.4%) or II genotype (15 years,
86.9%; 20 years, 69.1%; 25 years, 62.2%). These differences in
renal survival curve between DD versus ID or DD versus II were
statistically significant ( = 10.17, P < 0.005, = 11.93, P <
0.001, respectively). The renal survival rate in patients with ID
genotype was not significantly different from patients with II
genotype ( = 0.261, NS). Within the Group 2 patients, the time
lag from the onset of diabetes to the initiation of dialysis averaged
13.4 1.4 years for DD genotype, a time interval significantly
shorter than that for ID genotype (20.7 1.2 years, P < 0.01) or
II genotype (17.5 1.1 year, P < 0.01).
Discussion
Our data show an association between the ACE DD genotype
and progression to renal failure in NIDDM patients. In addition,
our analysis of the renal survival rate, defined as the percent of
patients without dialysis requirement, revealed that progression to
chronic renal failure is accelerated in patients with DD genotype
(Fig. 1). These results echo earlier observations in IgA nephrop-
athy [21] and in diabetic nephropathy in hypertensive IDDM [37].
Of note, in the 36 patients with albuminuria and stable renal
function, there was but one DD homozygote. This low DD
frequency was not significantly different from that in patients
without albuminuria. By contrast, the DD genotype in Group 2
Duration of diabetes, years
Fig. 1. Effect of ACE genotypes on the renal survival rate in NIDDM
patients. The "renal survival rate" in patients with DD genotype was lower
than that in patients with ID or II genotype. These differences between
DD (L) versus ID (0) or DD versus 11(ü) were statistically significant (x2
= 10.17, P < 0.005, y 11.93, P < 0.001, respectively). The time lag from
development of initial identifiable symptoms to the initiation of dialysis in
patients with DD genotype (averaged 13.4 1.4 years) was significantly
shorter than those in patients with ID genotype (20.7 1.2 years, P <
0.01) or II genotype (17.5 1.1 year, P < 0.01).
was more frequent than in the 36 patients with albuminuria but
without declining renal function. Overall, the majority of patients
with the DD genotype who developed albuminuria had progres-
sive loss of renal function within 10 years of diagnosis of diabetes.
Previous studies found that serum ACE level is elevated when
diabetic patients develop microalbuminuria [38, 391. In this re-
gard, Marre et al reported that the insertion/deletion polymor-
phism of the ACE gene is related to the presence of diabetic
nephropathy in IDDM patients with duration of DM of at least
five years [25]. Doria, Warram and Krowlewski also reported a
genetic influence of the ACE gene polymorphism on diabetic
nephropathy in IDDM [26]. In a recent study by Schmidt, Schone
and Ritz, however, no difference in distribution of ACE genotype
was found in diabetic patients with versus without nephropathy in
either IDDM or NIDDM [24]. Our results in many ways reiterate
those of Schmidt et al. They too analyzed patients who were
known to have diabetes for at least 10 years. The average serum
creatinine level of all their patients was 1.2 0.9 mg/dl and,
therefore, overlaps with our Group 1. In our Group 1 patients
with stable renal function, as in their entire group of patients with
nephropathy, no significant difference in the distribution of geno-
type for the ACE gene was seen between patients with versus
without albuminuria. In Schmidt's study, the distribution of ACE
genotype in patients on dialysis tended to be different (although
not statistically significantly) from patients without nephropathy.
Of note, the frequency of DD genotype is underestimated among
patients on dialysis. Figure 2 depicts the distribution of the DD
genotype in Group 2 patients who are on dialysis versus who are
still at pre-dialysis stages. For patients on dialysis, the frequency of
the DD genotype is shown, and related to the duration of dialysis.
In pre-dialysis patients and patients on dialysis for one year, the
frequencies of the DD genotype are 44% and 30% respectively. In
patients who have been on dialysis for > one year, the DD
Table 5. Clinical and laboratory features of all patients grouped by
genotype
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Fig. 2. Distribution of the DD genotype in Group 2 patients with and without
dialysis. For patients on dialysis, the frequency of the DD genotype is
shown according to the duration of dialysis. In pre-dialysis patients and
patients on dialysis for one year, the frequencies of the DD genotype
are 44% and 30%, respectively. In patients on dialysis for > one year, the
DD genotype is less frequent (18%) than in pre-dialysis patients and
patients on dialysis for one year.
genotype is less frequent (18%) than in those not on dialysis or
patients on dialysis for one year. Given that the ACE DD
genotype is a known risk factor of cardiovascular diseases, includ-
ing coronary heart disease and left ventricular hypertrophy, and
that the latter is a strong predictor of the mortality in dialysis
patients, it is conceivable that the ACE DD genotype increases
the mortality in dialysis patients, hence the prevalence of the DD
genotype in patients on chronic dialysis decreases year by year. If
this is indeed the case, the frequency of the DD genotype may be
underestimated in Group 2 patients with declining renal function,
especially among dialysis patients.
The decline in renal function in diabetic nephropathy occurs
slowly. Such progressive deterioration of renal function and
structure is not limited to diabetic nephropathy but, rather, is
common to many forms of chronic glomerular disease, including
IgA nephropathy, and several key pathophysiologic mechanisms
have been implicated in the progression [21. Our recent studies in
Japanese [19] and American Caucasian populations [20] indicate
that the DD genotype of ACE gene is associated with progressive
deterioration in renal function in IgA nephropathy. Another
recent report of patients with IgA nephropathy from England also
found a significant association of the D homozygosity with pro-
gressive loss of renal function in IgA nephropathy [21]. Although
our studies do not verify that the locus of the ACE gene deletion
polymorphism is indeed functional, earlier studies measuring
plasma and tissue ACE levels demonstrated a significantly posi-
tive correlation between the D allele and the renin-angiotensin
system in normal subjects [4—6] and in diabetic patients [25], that
is, the II genotype has the lowest ACE levels, the DD genotype
has the highest and the ID have intermediate levels. In a recent
study, Ueda et al showed that, in response to infusion of angio-
tensin I, those with the DD genotype display a greater blood
pressure increase than those with the II genotype [40]. In addition,
Todd et al have recently found that after ACE inhibitor admin-
istration, the absolute fall in serum ACE activity was significantly
greater in patients with DD genotype than that in patients with II
genotype [41]. Finally, our earlier study in patients with IgA
nephropathy showed that proteinuria was indeed significantly
decreased after ACE inhibition in patients with the DD genotype,
while it had no significant effect in patients with II or ID genotype
[19]. These data suggest that the D allele may be associated with
an activation of ACE.
We also examined the association between declining renal
function and two known gene variants of other components of the
renin-angiotensin system, namely M235T polymorphism of Atg
gene and A1166C polymorphism of AT1 gene. M235T polymor-
phism of Atg gene has been variably associated with hypertension
[13, 14, 35, 42, 43] and myocardial infarction [15, 161. In contrast
to these findings in hypertension and cardiovascular disease, the
M235T polymorphism of Atg gene was not associated in our study
with the progressive loss of renal function. Recent reports also
showed a correlation between the A1166C polymorphism of ATI
gene and hypertension [17, 18] and myocardial infarction [18]. In
our study on nephropathy, however, there was no significant
association between A1166C polymorphism and progression of
declining renal function. A recent report also showed that the TI
genotype in M235T polymorphism and the AT1C allele in
A1166C polymorphism enhance the relative risk of myocardial
infarction in patients with the DD genotype of ACE gene [16, 18].
Although the C allele alone was not significantly associated with
myocardial infarction, a significant synergistic effect of ACE DD
genotype plus C allele on the risk of myocardial infarction was
observed. For this reason, we too performed combined genotype
analysis. In our analysis, the Atg TI genotype in M235T polymor-
phism did not enhance the risk of progressive loss of renal
function in patients with the DD genotype. The risk of progressive
loss of renal function in patients with the DD genotype again was
not enhanced by the C allele in A1166C polymorphism. In our
control Japanese population, there was no CC genotype of
All 66C polymorphism and the frequency of C allele was only
8.5%, a level substantially lower than that reported for Caucasians
(approximately 30%). Our study, therefore, did not find any
significant impact of A1166C polymorphism in ATI gene on the
progression of diabetic nephropathy in Japanese patients. These
negative results may be attributed to the extremely low frequency
of C allele, or CC genotype in Japanese population. Nevertheless,
the results indicate that, overall, the A1166C polymorphism in
ATI gene dose not have a major impact on the progression of
diabetic nephropathy in Japanese population.
In summary, we observed a significant association between the
deletion/insertion polymorphism of the ACE gene and progres-
sive loss of renal function in patients with diabetic nephropathy.
Moreover, our analysis of time to end-stage renal disease indi-
cates that the ACE DD genotype accelerates the progression to
chronic renal failure in diabetic nephropathy. In contrast to these
findings in ACE gene polymorphism, gene polymorphisms of
other components of the renin-angiotensin system, specifically the
M235T polymorphism of Atg gene and the A1166C polymor-
phism in AT1 gene, were not associated with progressive loss of
renal function. These results collectively indicate that the ACE
DD genotype alone is a highly reliable predictor of a poor
prognosis in NIDDM.
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Appendix
Abbreviations are: ACE, angiotensin I converting enzyme; Atg, angio-
tensinogen; AT1, angiotensin II type 1 receptor; IDDM; insulin depen-
dent diabetes; NIDDM; non-insulin dependent diabetes; I, insertion; D,
deletion.
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